Consensus guidelines

Treatment planning and options

Charles E. Argoff, Misha Miroslav Backonja, Miles J. Belgrade, Gary J. Bennett, Michael Clark, B. Eliot Cole, David A. Fishbain, Gordon A. Irving, Bill H. McCarberg, Michael J. McLean

Research output: Contribution to journal › Article

Abstract

Despite the number of patients affected by diabetic peripheral neuropathic pain (DPNP), little consensus exists about the pathophysiology, best diagnostic tools, and primary treatment choices. Theories about tlie causes of DPNP are Inextricably linked with the causes of dietetic neuropathies, yet most patients with such neuropathies do not experience pain. The factors that differentiate patients with pain from those without remain unknown and are the subject of much research. When choosing treatment for patients with DPNP, physicians are confronted with a myriad of choices, none of which has been shown to be effective for all patients. This article reviews the evidence for these treatments and attempts to guide physicians in choosing those treatments based on evidence from well-designed clinical trials to support their use. Two agents, duioxetine and pregabalin, are formally approved by the Food and Drug Administration for the treatment of DPNIP. Dn addition, several other agents, Including the tricyclic class of antidepressants, have been effective in clinical trials. Ultimately, treatment choice must also Include consideration of adverse effects, individual patient factors such as comorbidities, and often cost.

Original languageEnglish (US)
JournalMayo Clinic Proceedings
Volume81
Issue number4 SUPPL.
StatePublished - 2006

Fingerprint

Consensus
Guidelines
Neuralgia
Therapeutics
Clinical Trials
Physicians
Pain
Dietetics
Tricyclic Antidepressive Agents
United States Food and Drug Administration
Comorbidity
Costs and Cost Analysis
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Argoff, C. E., Backonja, M. M., Belgrade, M. J., Bennett, G. J., Clark, M., Cole, B. E., ... McLean, M. J. (2006). Consensus guidelines: Treatment planning and options. Mayo Clinic Proceedings, 81(4 SUPPL.).

Consensus guidelines : Treatment planning and options. / Argoff, Charles E.; Backonja, Misha Miroslav; Belgrade, Miles J.; Bennett, Gary J.; Clark, Michael; Cole, B. Eliot; Fishbain, David A.; Irving, Gordon A.; McCarberg, Bill H.; McLean, Michael J.

In: Mayo Clinic Proceedings, Vol. 81, No. 4 SUPPL., 2006.

Research output: Contribution to journal › Article

Argoff, CE, Backonja, MM, Belgrade, MJ, Bennett, GJ, Clark, M, Cole, BE, Fishbain, DA, Irving, GA, McCarberg, BH & McLean, MJ 2006, 'Consensus guidelines: Treatment planning and options', Mayo Clinic Proceedings, vol. 81, no. 4 SUPPL..
Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark M, Cole BE et al. Consensus guidelines: Treatment planning and options. Mayo Clinic Proceedings. 2006;81(4 SUPPL.).
Argoff, Charles E. ; Backonja, Misha Miroslav ; Belgrade, Miles J. ; Bennett, Gary J. ; Clark, Michael ; Cole, B. Eliot ; Fishbain, David A. ; Irving, Gordon A. ; McCarberg, Bill H. ; McLean, Michael J. / Consensus guidelines : Treatment planning and options. In: Mayo Clinic Proceedings. 2006 ; Vol. 81, No. 4 SUPPL.
@article{a522c534d0e24b2881c29575d4b8fd5d,
title = "Consensus guidelines: Treatment planning and options",
abstract = "Despite the number of patients affected by diabetic peripheral neuropathic pain (DPNP), little consensus exists about the pathophysiology, best diagnostic tools, and primary treatment choices. Theories about tlie causes of DPNP are Inextricably linked with the causes of dietetic neuropathies, yet most patients with such neuropathies do not experience pain. The factors that differentiate patients with pain from those without remain unknown and are the subject of much research. When choosing treatment for patients with DPNP, physicians are confronted with a myriad of choices, none of which has been shown to be effective for all patients. This article reviews the evidence for these treatments and attempts to guide physicians in choosing those treatments based on evidence from well-designed clinical trials to support their use. Two agents, duioxetine and pregabalin, are formally approved by the Food and Drug Administration for the treatment of DPNIP. Dn addition, several other agents, Including the tricyclic class of antidepressants, have been effective in clinical trials. Ultimately, treatment choice must also Include consideration of adverse effects, individual patient factors such as comorbidities, and often cost.",
author = "Argoff, {Charles E.} and Backonja, {Misha Miroslav} and Belgrade, {Miles J.} and Bennett, {Gary J.} and Michael Clark and Cole, {B. Eliot} and Fishbain, {David A.} and Irving, {Gordon A.} and McCarberg, {Bill H.} and McLean, {Michael J.}",
year = "2006",
language = "English (US)",
volume = "81",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Consensus guidelines

T2 - Treatment planning and options

AU - Argoff, Charles E.

AU - Backonja, Misha Miroslav

AU - Belgrade, Miles J.

AU - Bennett, Gary J.

AU - Clark, Michael

AU - Cole, B. Eliot

AU - Fishbain, David A.

AU - Irving, Gordon A.

AU - McCarberg, Bill H.

AU - McLean, Michael J.

PY - 2006

Y1 - 2006

N2 - Despite the number of patients affected by diabetic peripheral neuropathic pain (DPNP), little consensus exists about the pathophysiology, best diagnostic tools, and primary treatment choices. Theories about tlie causes of DPNP are Inextricably linked with the causes of dietetic neuropathies, yet most patients with such neuropathies do not experience pain. The factors that differentiate patients with pain from those without remain unknown and are the subject of much research. When choosing treatment for patients with DPNP, physicians are confronted with a myriad of choices, none of which has been shown to be effective for all patients. This article reviews the evidence for these treatments and attempts to guide physicians in choosing those treatments based on evidence from well-designed clinical trials to support their use. Two agents, duioxetine and pregabalin, are formally approved by the Food and Drug Administration for the treatment of DPNIP. Dn addition, several other agents, Including the tricyclic class of antidepressants, have been effective in clinical trials. Ultimately, treatment choice must also Include consideration of adverse effects, individual patient factors such as comorbidities, and often cost.

AB - Despite the number of patients affected by diabetic peripheral neuropathic pain (DPNP), little consensus exists about the pathophysiology, best diagnostic tools, and primary treatment choices. Theories about tlie causes of DPNP are Inextricably linked with the causes of dietetic neuropathies, yet most patients with such neuropathies do not experience pain. The factors that differentiate patients with pain from those without remain unknown and are the subject of much research. When choosing treatment for patients with DPNP, physicians are confronted with a myriad of choices, none of which has been shown to be effective for all patients. This article reviews the evidence for these treatments and attempts to guide physicians in choosing those treatments based on evidence from well-designed clinical trials to support their use. Two agents, duioxetine and pregabalin, are formally approved by the Food and Drug Administration for the treatment of DPNIP. Dn addition, several other agents, Including the tricyclic class of antidepressants, have been effective in clinical trials. Ultimately, treatment choice must also Include consideration of adverse effects, individual patient factors such as comorbidities, and often cost.

UR - http://www.scopus.com/inward/record.url?scp=33645689140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645689140&partnerID=8YFLogxK

M3 - Article

VL - 81

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4 SUPPL.

ER -

Access to Document